Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.
Studies were designed to investigate whether the cellular immunodeficiency state observed in human glioblastoma patients could be due to inhibitory factors released by the tumor cells. Cultured human glioblastoma cells were found to secrete an interleukin 1-like factor (m.w. 22,000) and a factor (m.w. 97,000) that inhibits interleukin 2 (IL 2)-dependent T cell mechanisms. This is demonstrated by its inhibitory effect on the IL 2-induced proliferation of T cell clones and on the induction of alloreactive cytotoxic T cells in mixed lymphocyte cultures. Additionally the glioblastoma cell-derived 97,000-m.w. factor inhibited growth of neuroblasts but not of fibroblasts and thus shares the characteristics of the neuroblast growth inhibition factor (NGIF) previously detected in the supernatant of fetal rat glia cell cultures. If released by glioblastoma cells in vivo, the factor may contribute to impaired immunosurveillance and to the cellular immunodeficiency state detected in the patients.
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D005347:Fibroblasts / Q000166:cytology; D005910:Glioma / Q000032:analysis / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis* / Q000502:physiology; D007376:Interleukin-2 / Q000502:physiology*; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000096:biosynthesis*; D051379:Mice; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000276:immunology* / Q000494:pharmacology; D009474:Neurons / Q000166:cytology; D013601:T-Lymphocytes / Q000276:immunology
D007375:Interleukin-1; D007376:Interleukin-2; D008222:Lymphokines; D009363:Neoplasm Proteins